Interest in Novel Lymphoma Drug Expands to Two Key Subtypes

(MedPage Today) — HOUSTON — Already indicated for relapsed/refractory follicular lymphoma, the bispecific antibody mosunetuzumab (Lunsumio) showed early promise for improving outcomes in two key lymphoma subtypes, according to studies reported…